This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment
Public ClinicalTrials.gov record NCT00150800. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multi-center, Follow-up Trial to Evaluate Long Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment.
Study identification
- NCT ID
- NCT00150800
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 668 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2006 (Type not available)
- Primary completion
- Sep 2017 (Actual)
- Completion
- Sep 2017 (Actual)
- Last update posted
- Aug 17, 2021
2006 – 2017
United States locations
- U.S. sites
- 46
- U.S. states
- 27
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| N01199 1051 | Phoenix | Arizona | — | — |
| N01199 1362 | Phoenix | Arizona | — | — |
| N01199 1374 | Tucson | Arizona | — | — |
| N01199 1050 | Little Rock | Arkansas | — | — |
| N01199 1078 | Fresno | California | — | — |
| N01199 1392 | Newport Beach | California | — | — |
| N01199 1087 | San Francisco | California | — | — |
| N01199 1368 | San Francisco | California | — | — |
| N01199 1396 | Atlanta | Georgia | — | — |
| N01199 1385 | Augusta | Georgia | — | — |
| N01199 1356 | Chicago | Illinois | — | — |
| N01199 1388 | Springfield | Illinois | — | — |
| N01199 1375 | Wichita | Kansas | — | — |
| N01199 1364 | Lexington | Kentucky | — | — |
| N01199 1380 | Louisville | Kentucky | — | — |
| N01199 1052 | Paducah | Kentucky | — | — |
| N01199 1083 | Ruston | Louisiana | — | — |
| N01199 1373 | Baltimore | Maryland | — | — |
| N01199 1086 | Bethesda | Maryland | — | — |
| N01199 1077 | Burlington | Massachusetts | — | — |
| N01199 1391 | Detroit | Michigan | — | — |
| N01199 1395 | Detroit | Michigan | — | — |
| N01199 1071 | Grand Rapids | Michigan | — | — |
| N01199 1389 | Saint Paul | Minnesota | — | — |
| N01199 1079 | Tupelo | Mississippi | — | — |
| N01199 1360 | Chesterfield | Missouri | — | — |
| N01199 1352 | St Louis | Missouri | — | — |
| N01199 1069 | Great Falls | Montana | — | — |
| N01199 1062 | Toms River | New Jersey | — | — |
| N01199 1053 | New York | New York | — | — |
| N01199 1365 | Rochester | New York | — | — |
| N01199 1366 | Cincinnati | Ohio | — | — |
| N01199 1054 | Columbus | Ohio | — | — |
| N01199 1359 | Portland | Oregon | — | — |
| N01199 1055 | Philadelphia | Pennsylvania | — | — |
| N01199 1059 | Philadelphia | Pennsylvania | — | — |
| N01199 1081 | Greenville | South Carolina | — | — |
| N01199 1061 | Nashville | Tennessee | — | — |
| N01199 1084 | Dallas | Texas | — | — |
| N01199 1394 | Dallas | Texas | — | — |
| N01199 1064 | Houston | Texas | — | — |
| N01199 1082 | Salt Lake City | Utah | — | — |
| N01199 1367 | Charlottesville | Virginia | — | — |
| N01199 1393 | Richmond | Virginia | — | — |
| N01199 1376 | Seattle | Washington | — | — |
| N01199 1369 | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00150800, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2021 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00150800 live on ClinicalTrials.gov.